Seborrheic Keratosis Treatment Market By Treatment Type (Surgical Treatment, Topical Solution Treatment) - Growth, Share, Opportunities & Competitive Analysis, 2018 -2026

Market Excerpt

The global market for seborrheic keratosis (SK) treatment is expected to reach $1,320.8 million by 2026. The rising popularity of cosmetic and aesthetic products, as well as the high prevalence of seborrheic keratosis, are thought to be the primary factors driving the seborrheic keratosis treatment market. This market is further characterized by the presence of a multitude of players operating in various treatment modules such as laser, cryosurgery, surgical removal, etc. In addition, with promising topical candidates in the pipeline, the seborrheic keratosis treatment market will witness a boost in future growth.

According to an article published in 2015 by Jackson JM et al. (Jackson JM et al., Current Understanding of Seborrheic Keratosis: Prevalence, Etiology, Clinical Presentation, Diagnosis, and Management, J Drugs Dermatol, 2015 Oct; 14(10):1119–25), an estimated 83 million people were affected by seborrheic keratosis in 2014, and dermatologists reported an average diagnosis of 155 patients per month with the disease in the United States in 2015. Of these patients, 33% had over 15 lesions, and 67% had 15 or fewer lesions. In addition, with the surge in the geriatric population, the eligible patient pool for SK treatment further expands, thus driving the overall market growth. Furthermore, it was estimated that around 43 percent of the patients opt for surgical treatment due to the benign and less painful nature of the growth. Furthermore, the lack of reimbursement policies for treatment in both developed and developing countries stifles market growth. Reimbursement is considered for seborrheic keratosis treatment only in cases of bleeding, itching, and other medical reasons and not for cosmetic treatments. Manufacturers are investing in research and development for non-invasive and non-surgical treatment methods for seborrheic keratosis. For instance, in 2017, a topical solution—Eskata, 40% hydrogen peroxide—was approved for the treatment.

Market Synopsis

"Approval of topical solutions will drive the market during the forecast period."

Several topical solutions are used as off-label therapeutics to reduce the height of seborrheic keratosis, including ammonium lactate and alpha-hydroxy acids, among others. However, in 2017, the FDA approved hydrogen peroxide (40 percent solution), branded as Eskata and developed by Aclaris Therapeutics, Inc., for the treatment of seborrheic keratosis. The product will be available in the United States after its expected commercialization in the first half of 2018. A few other topical solutions are currently in the pipeline and are expected to be approved within the forecast period. The development of cost-effective and non-surgical treatment options is anticipated to drive the market, coupled with rising awareness in the patient population.

Cryosurgery is the most preferred treatment for seborrheic keratosis, followed by other surgical treatment options such as electrocautery, curettage, etc. With the adoption of laser treatment methods, the market for seborrheic keratosis treatments will experience an upsurge. In 2017, the cryosurgery segment led the market in terms of market value and will retain its lead during the forecast period. High preference by physicians due to significant treatment outcomes mainly contributes to the dominance of this segment. The demand for topical solution treatment (Eskata) as a viable treatment option in the market after its commercialization in 2018 significantly contributed to the market's growth.

"Asia Pacific will see profitable growth during the forecast period."

Asia Pacific is expected to experience the fastest market growth during the forecast period owing to the growing prevalence of SK and the increasing adoption of surgical treatment in the region. Since there is no clarity on the commercialization of Eskata (40% hydrogen peroxide) in the region, other treatment segments in the region will not face any substantial competition. In 2017, North America dominated the global seborrheic keratosis market owing to the adoption of advanced treatment options and awareness of the disease. Additionally, a majority of the players are headquartered in the United States, which further contributes to the supremacy of North America. In terms of market value, North America was followed by Europe in 2017. In Europe, it has been estimated that over 90% of adults aged 60 or more have at least one or more SK lesions. Approximately 40%–60% of the entire population in Europe has at least one SK lesion. Northern Europe has a higher prevalence of seborrheic keratosis.

"Cryosurgery devices are among the major revenue contributors to the manufacturers."

Although several options are available on the market for seborrheic keratosis treatment, cryosurgery is the most preferred method due to its proven better treatment outcomes. Preference for cryosurgery as a viable treatment method, combined with high prevalence, has resulted in an increase in cryosurgery device installation in the United States and other developed countries. Furthermore, players are investing in the introduction of cost-effective and non-surgical treatments for the disease. For instance, EpiPharm AG, a Switzerland-based company, is investing in new and non-invasive therapies for the treatment of benign skin tumors. EPI-SK14, a pipeline product of EpiPharm, is in Phase II clinical trials and is a non-invasive treatment for seborrheic keratosis. Furthermore, manufacturers have a diverse product portfolio, which satisfies the growing demand from the disease burden.

Periods of History and Forecast

Each segment is analyzed from 2016 to 2026, considering 2017 as the base year for the study. The compound annual growth rate (CAGR) is calculated for the forecast period from 2018 to 2026 for each segment.

Report Scope by Segments

This market research report on the seborrheic keratosis treatment market provides a market outlook as well as quantitative research on global trends. The report provides a detailed outline of the global seborrheic keratosis treatment market by categorizing the market in terms of treatment type and geography. The objective of publishing this extensive research report is to aid the stakeholders in making decisions and taking strategic initiatives in the seborrheic keratosis treatment market.

This report further describes the major qualitative assessment factors, including key market trends, market drivers, and market restraints, to aid in a better understanding of the global seborrheic keratosis treatment market. Furthermore, the key players are graphically mapped based on their product offerings, market strategies, and business strengths. The report also provides an attractive investment proposition based on extensive geographical research. Key players profiled in the report include Aclaris Therapeutics, Inc., Cortex Technology ApS, CryoConcepts LP, Cryoswiss GmbH, EpiPharm AG, H&O Equipments SA, Orasure Technologies, Inc., Special Medical Technology Co., Ltd., and Wallach Surgical Devices, Inc.

Key questions are answered in this report.

  • Which are the prominent segments in seborrheic keratosis treatment?
  • What will be the effect of topical solution approval by the FDA on the global market?
  • What are the current market trends in the seborrheic keratosis treatment industry and the most valuable growth opportunities for the players?
  • Which prominent geographies are appropriate for product launches?
  • Which segment is the fastest-growing segment during the forecast period?
  • What is the size of the North American market for the treatment of seborrheic keratosis, and how do the other regional markets compare to the global competition? 

Frequently Asked Questions:

The market for Seborrheic Keratosis Treatment is expected to reach US$ 1,320.8 Mn in 2026.

The Seborrheic Keratosis Treatment market is expected to see significant CAGR growth over the coming years,at XX%.

The report is forecasted from 2018-2026.

The base year of this report is 2017.

Aclaris Therapeutics Inc.,Cortex Technology ApS,CryoConcepts LP,Cryoswiss GmbH,DRE Medical, Inc. are some of the major players in the global market.

Choose License Type
Trusted By
Published Date:  Apr 2018
Category:  Medical Devices
Report ID:   59075
Report Format:   PDF
Pages:   120
Rating:    4.4 (55)
Delivery Time: 24 Hours to 48 Hours   
Connect With Us
24/7 Research Support